Theriva Biologics, Inc.
$0.41
▲
1.46%
2026-04-21 09:52:01
therivabio.com
ASE: TOVX
Explore Theriva Biologics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$18.89 M
Current Price
$0.41
52W High / Low
$1.5 / $0.16
Stock P/E
—
Book Value
$0.43
Dividend Yield
—
ROCE
-85.21%
ROE
-1.38%
Face Value
—
EPS
$-2.08
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
0.47
Debt / Equity
17.09
Current Ratio
1.74
Quick Ratio
1.74
Forward P/E
-1.15
Price / Sales
—
Enterprise Value
$0.16 M
EV / EBITDA
-0.01
EV / Revenue
—
Rating
Strong Buy
Target Price
$2.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Abeona Therapeutics Inc. | $5.48 | 4.39 | $312.63 M | — | -47.08% | 70.05% | $7.54 / $4 | $2.89 |
| 2. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 3. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 4. | GRI Bio, Inc. | $2.51 | — | $3.68 M | — | -198.85% | -2.38% | $80.36 / $2.1 | $12.07 |
| 5. | AEON Biopharma, Inc. | $1.07 | — | $25.81 M | — | 252.78% | -46.26% | $1.45 / $0.38 | $-4.54 |
| 6. | Benitec Biopharma Inc. | $13.99 | — | $483.71 M | — | -42.71% | -33.5% | $17.15 / $9.85 | $5.47 |
| 7. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.06 M | -4.44 M | -13.13 M | -4.42 M | -4.58 M | — |
| Net Profit | -2 M | -4.36 M | -13.06 M | -4.32 M | -4.45 M | — |
| EPS in Rs | -0.04 | -0.1 | -0.28 | -0.09 | -0.1 | -6.81 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -24.05 M | -19.43 M | -21.43 M | -21.58 M |
| Net Profit | -23.74 M | -25.65 M | -18.35 M | -19.68 M |
| EPS in Rs | -0.52 | -0.56 | -0.4 | -0.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 38.24 M | 35.35 M | 55.22 M | 71.86 M |
| Total Liabilities | 22.86 M | 16.29 M | 15.52 M | 17.3 M |
| Equity | 15.38 M | 19.07 M | 39.7 M | 54.56 M |
| Current Assets | 17.47 M | 16.28 M | 27.4 M | 45.52 M |
| Current Liabilities | 10.01 M | 7.58 M | 6.74 M | 7.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -16.67 M | -16.94 M | -19 M | -19.08 M |
| Investing CF | -0.04 M | -0 M | -0.2 M | -4.4 M |
| Financing CF | 18.19 M | 5.5 M | 0.62 M | -1.93 M |
| Free CF | -16.7 M | -16.94 M | -19.2 M | -19.2 M |
| Capex | -0.04 M | -0 M | -0.2 M | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -39.81% | 6.79% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-26 | 1:0.04 |
| 2022-07-25 | 1:0.1 |